SCHEMBL23728247

SCHEMBL23728247

[CH2]CC(=O)CC(O)CCCCCCCCCCC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 8/20 0.63
FFAR1 O14842 2/20 0.52
FFAR4 Q5NUL3 1/20 0.52
NFKB1 P19838 1/20 0.50
TRPV1 Q8NER1 1/20 0.49
CYP3A4 P08684 2/20 0.43
HTR1A P08908 2/20 0.43
CYP2C8 P10632 2/20 0.43
CYP2D6 P10635 2/20 0.43
CYP2A6 P11509 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2B6 P20813 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2E1 P05181 1/20 0.43
LTA4H P09960 1/20 0.43
FAAH O00519 1/20 0.42
PSMD14 O00487 1/20 0.42
PLA2G1B P04054 1/20 0.42
HSP90AA1 P07900 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23728329 1.00 GPR84 (0.63) GPR84FFAR1FFAR4NFKB1TRPV1
SCHEMBL23728242 1.00 GPR84 (0.63) GPR84FFAR1FFAR4NFKB1TRPV1
SCHEMBL23728321 0.98 GPR84 (0.60) GPR84FFAR1FFAR4NFKB1TRPV1
SCHEMBL14640803 0.84 GPR84 (0.68) GPR84FFAR1FFAR4NFKB1TRPV1
SCHEMBL17002061 0.84 GPR84 (0.68) GPR84FFAR1FFAR4NFKB1TRPV1
SCHEMBL23727934 0.84 GPR84 (0.41) GPR84FFAR1FFAR4NFKB1TRPV1
SCHEMBL12419013 0.82 GPR84 (0.66) GPR84FFAR1FFAR4NFKB1TRPV1
SCHEMBL9449753 0.82 GPR84 (0.66) GPR84FFAR1FFAR4NFKB1TRPV1
SCHEMBL12396669 0.82 GPR84 (0.66) GPR84FFAR1FFAR4NFKB1TRPV1
SCHEMBL8817418 0.82 GPR84 (0.66) GPR84FFAR1FFAR4NFKB1TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US disclosed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB GPR84 1793/4885FFAR1 1328/4885FFAR4 1781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.